Whitehawk Net Income From Continuing Ops from 2010 to 2026
| WHWK Stock | 2.85 0.16 5.32% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -57.3 M | Current Value -60.2 M | Quarterly Volatility 34.4 M |
Check Whitehawk Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Whitehawk Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 117.5 K, Interest Expense of 131.7 K or Selling General Administrative of 26.4 M, as well as many indicators such as Price To Sales Ratio of 3.59, Dividend Yield of 0.0165 or PTB Ratio of 1.54. Whitehawk financial statements analysis is a perfect complement when working with Whitehawk Therapeutics Valuation or Volatility modules.
Whitehawk | Net Income From Continuing Ops | Build AI portfolio with Whitehawk Stock |
Historical Net Income From Continuing Ops data for Whitehawk Therapeutics serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Whitehawk Therapeutics represents a compelling investment opportunity.
Latest Whitehawk Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Whitehawk Therapeutics over the last few years. It is Whitehawk Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Whitehawk Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Whitehawk Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (26,813,347) | |
| Coefficient Of Variation | (128.46) | |
| Mean Deviation | 30,198,684 | |
| Median | (3,478,000) | |
| Standard Deviation | 34,444,177 | |
| Sample Variance | 1186.4T | |
| Range | 106.6M | |
| R-Value | (0.74) | |
| Mean Square Error | 578T | |
| R-Squared | 0.54 | |
| Significance | 0.0007 | |
| Slope | (5,027,638) | |
| Total Sum of Squares | 18982.4T |
Whitehawk Net Income From Continuing Ops History
About Whitehawk Therapeutics Financial Statements
Whitehawk Therapeutics investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Whitehawk Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -57.3 M | -60.2 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Whitehawk Therapeutics Correlation against competitors. For more information on how to buy Whitehawk Stock please use our How to buy in Whitehawk Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Whitehawk Therapeutics. Anticipated expansion of Whitehawk directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Whitehawk Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.64) | Revenue Per Share | Quarterly Revenue Growth 0.335 | Return On Assets | Return On Equity |
Investors evaluate Whitehawk Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Whitehawk Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Whitehawk Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Whitehawk Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Whitehawk Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Whitehawk Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.